Monoclonal Antibodies as Therapeutic AgentsFundamentals, Therapeutic Applications and Latest Advances

Launched October 2007 26 lectures
Prof. Herman Waldmann
Sir William Dunn School of Pathology, University of Oxford, UK

It has long been recognised that the precision of antibody recognition offers attractive prospects for therapeutic targeting. Since the discovery of monoclonal antibodies by Milstein and Kohler in 1975, antibody therapy has been evolving as a significant player in the biopharmaceutical industry. Although promise has been high progress has been... read moreless rapid than hoped. In part this is a reflection of the state of our understanding of disease pathogenesis, the, perhaps unrealistic wish to have great drugs with minimal side effects, and the difficulties in establishing proper parameters of efficacy and benefit. In part some of these problems have been overcome, whilst others remain active areas of ongoing research.

The talks will target growth areas of therapy, and the improvements to antibodies and their application needed to achieve the desired goals.